Abstract
The poxvirus Modified Vaccinia virus Ankara (MVA) is a safe and versatile licensed vaccine and viral vector, yet its immunogenicity remains improvable, as it often requires multiple doses for optimal protection and also induces waning of antibody responses. To enable more rational optimization of MVA-based vaccines, we developed a mechanistic and executable systems vaccinology framework based on Boolean modeling to capture the dynamics of vaccine-induced immune responses. We constructed and calibrated a Boolean network of the MVA-induced immune response by integrating literature-derived mechanisms with longitudinal in vivo experimental data. The model accurately reproduced immune dynamics with high fidelity and, importantly, was validated against independent datasets of genetically modified MVA vaccines, demonstrating strong predictive capacity. Using this framework, we performed in silico perturbations to evaluate novel genetically modified MVA mutants derived from expert knowledge. To further guide rational design, we built two other vaccine-induced response Boolean networks: one describing the MVA response in a broader fashion, the other modeling the YF-17D yellow fever vaccine response that represents a reference for durable protection after single-dose immunization. Comparative analysis of network topology and dynamics revealed shared and divergent features that informed strategies to enhance MVA-induced responses by reorienting them toward YF-17D-like immune signatures, and allowed us to design and test virtually two new genetically modified MVA deletion mutants. Throughout this work, we exploited the executable nature of the models of response to MVA to simulate perturbations, identifying potential targets to boost immunogenicity. Together, this work establishes executable Boolean modeling as a valuable predictive tool for systems vaccinology and provides a generalizable framework for the rational design and optimization of next-generation MVA-based vaccines.
Introduction
The poxvirus Modified Vaccinia virus Ankara (MVA) is a highly attenuated strain of vaccinia virus (VACV) that does not fully replicate in mammalian cells, and is widely used as a safe and versatile viral vaccine vector. Originally developed as a third-generation smallpox vaccine, MVA is now licensed for use against mpox to face the 2022 outbreak 1–3 and as a recombinant booster vaccine in Ebola vaccination regimens 4, and serves as a versatile vector for developing vaccines against numerous infectious diseases and cancers 5–7. MVA vaccines are known for their strong immunogenicity and protective efficacy against poxviruses, as they elicit robust B- and T-cell responses while maintaining an excellent safety profile 8–11. The induction of long-lasting antigen-specific adaptive immunity by vaccination is known to be strongly orchestrated and modulated by the early innate immune responses 12–14 For MVA, specifically, early defense mechanisms have been shown to strongly affect long-term antibody and T-cell responses in preclinical models 15,16 and in clinical trials in human volunteers 17. Nevertheless, its immunogenicity should be improved, as a two-dose regimen is necessary to induce comparable protection against mpox in macaques to a single-dose strategy with a live VACV vaccine 18, and the neutralizing anti-mpox antibody response wanes rapidly, particularly in smallpox vaccine-naïve individuals 19,20. Furthermore, the molecular and cellular mechanisms linking early innate sensing of MVA to durable adaptive immunity remain only partially understood, limiting efforts to rationally optimize this vaccine vector.
The MVA genome, sequenced in 1998 21, lacks 15% of the parental VACV genome, including several viral immune evasion and host-range genes. However, multiple viral immunomodulatory genes still remain conserved in the MVA genome and actively modulate and often inhibit host innate pathways 22. Over the past two decades, targeted deletions of such genes have yielded MVA recombinants with enhanced immunogenicity 23–29, demonstrating that MVA vector engineering can reshape host immune responses. Yet, identifying which viral or host pathways should be modulated to achieve optimal immunogenicity remains largely empirical, highlighting the need for predictive frameworks capable of linking molecular mechanisms to system-wide immune outcomes.
The advent of systems vaccinology, an interdisciplinary approach that leverages computational and experimental methods to understand and predict vaccine-induced immune responses, opens the door to a more rational definition of vaccine optimization strategies 30. To guide the rational search for optimized MVA-based vaccines, one promising approach is to mimic the characteristics of a highly effective vaccine-induced response. In this context, the live-attenuated YF-17D yellow fever vaccine represents a compelling benchmark. Considered as a paradigm of vaccine success, YF-17D combines an excellent safety profile (despite rare, around 1/250000 administrations, but sometimes severe adverse events) with lifelong protection after a single dose 31. Moreover, it has been emphasized the learning potential from YF-17D, especially as its mechanisms of action have been progressively elucidated through systems biology approaches 32. To date, such studies have provided detailed descriptions of the YF-17D-induced response and identified mechanisms of action and predictive markers of immunogenicity and protective efficacy 33–36, as well as unique features that distinguish it from other vaccines 37. YF-17D infects dendritic cells (DCs) and stimulates multiple Toll-like receptor (TLR) pathways 38–44. Building on this knowledge, nanoparticles containing antigens combined with ligands for one or more TLRs were designed and evaluated in mice. The simultaneous stimulation of multiple TLR pathways was shown to induce stronger adaptive responses than single-pathway activation 45. Similarly, the immunogenicity of a dengue vaccine candidate was enhanced by adjuvating the envelope antigen with the combination of TLR agonists mimicking the best immune signatures of early responses to YF-17D 46. These examples illustrate how mechanistic understanding ofYF-17D can inform rational vaccine design.
In 47, we conducted a non-human primate (NHP) study to characterize early immune responses following MVA vaccination. Using cytometry, transcriptomics, and cytokine profiling combined with systems biology approaches, including pathway enrichment, dimensionality reduction, and co-expression network analyses, we delineated the cascade of cellular and molecular events initiated at the vaccine injection site, in draining lymph nodes, and in blood. We linked the magnitude and quality of early innate effector responses with the orientation of subsequent adaptive immunity and highlighted a potential role for myeloid-derived suppressor cells (MDSCs). Building on these findings, dynamic mechanistic modeling represents a logical next step to extend our knowledge and understanding and improve our capacity to optimize MVA-induced immune responses. By enabling the simulation of MVA- and YF-17D-elicited immune dynamics over time, such models could provide insight into shared and distinct mechanisms and thereby guide the rational optimization of MVA vaccination strategies.
Boolean modeling is a dynamic and mechanistic formalism that translates the continuous expressions and dynamics of the underlying biological systems into binary states and qualitative changes 48. It has been successfully applied to diverse contexts, ranging from cellular expression and plasticity 49–51 to the pathogenesis of cancer and infectious diseases and potential therapeutic interventions 52–56, but it has rarely been used to model vaccine-induced immune responses, in contrast to statistic modelling or ordinary differential equation (ODE)-based modelling 57–64 Because Boolean formalism implies a substantial approximation with regard to the underlying biological system, it requires careful validation against experimental observations 49,53,65. Importantly, to avoid overfitting and actually to challenge computational models, the validation should be performed in conditions outside the scope of the data used to build the models 66.
In this work, we applied the Boolean formalism to the modeling of vaccine-induced immune responses. We first build a Boolean network of the MVA-induced immune response by integrating literature-curated existing knowledge with context-specific experimental data from our MVA preclinical study in NHPs 47. The resulting model precisely recapitulated the MVA-induced immune response with high fidelity. To validate the underlying mechanisms and assess its extrapolation capacity, we leveraged published immune responses data from genetically modified MVA vectors 23,25,28. By comparing perturbed simulation outcomes with their independent experimental observations, we demonstrated strong concordance, supporting the validity of both the model and, by extension, the modeling strategy, as well as the relevance and usefulness of Boolean modeling in vaccinology. We then exploited the executable nature of Boolean networks in both supervised and unsupervised modes to discover strategies for enhancing MVA immunogenicity. We first evaluated in silica two novel MVA mutants derived from expert knowledge by perturbing the model of response to MVA. Next, we built two comparable Boolean models of MVA- and YF-17D-induced immune responses in NHPs and performed static and dynamic comparative analyses on these networks to identify shared and divergent regulatory features. This comparative framework enabled the virtual identification and evaluation of molecular targets to reorient MVA-induced immune responses toward YF-17D-like immune signatures.
Materials and methods
The Boolean modeling formalism
Boolean networks consist of nodes with binary states that can be seen as on/off switches, and logical rules that determine state transitions. Each node is regulated by a defined set of upstream nodes and an associated update rule formalized through logical operators, such as AND, OR, NOT or XOR. The global state of the Boolean network is defined by the concurrent states of all nodes. Its transitions from one state to the next depend on the chosen semantics or update scheme, which determines what variables will have their state updated, and the functions they have been assigned. Two main semantics are typically used: synchronous updating, in which all variables are updated simultaneously for every transition, or asynchronous updating, in which subsets of nodes are updated at each step. In this work, we employed a synchronous update scheme to ensure deterministic trajectories and facilitate comparison with discretized time-series experimental data. Starting from an initial state, the Boolean network follows a trajectory that will eventually reach an asymptotic regime, or attractor, which can be a single steady state or a cycle pattern of states 67.
Boolean modeling formalism is ideally suited for prediction tasks. Its inherent mechanistic information allows for hypotheses beyond the initial data scope. Additionally, its binary variables facilitate system perturbation and output interpretation. In practice, one can force the initial or constant state of one or more network nodes to either O/off or 1/on and observe how the other nodes are affected, i.e. which nodes remain stable and which ones are up- or downregulated.
Boolean naïve network construction
To build relevant Boolean networks of biological systems, a classical approach would rely on the manual curation of known interactions and their conversion into logical functions. To allow for the construction of larger networks and reduce our dependency on expert knowledge about the mechanisms described, we leveraged existing interaction information from curated signaling pathway databases. We used the Living Map app on the 3DEXPERIENCE platform (BIOVIA, Dassault Systèmes) to aggregate signaling pathways from the KEGG database 68 and convert molecular interaction information into a single executable Boolean network. Because certain biological processes represented in KEGG (e.g., phosphorylation or ubiquitination) do not have direct logical equivalents, this conversion of signaling pathways into a Boolean network can lead to information loss and disconnection of nodes from the rest of the network. To mitigate this issue, we reconnected isolated nodes back to the main structure using oriented protein-protein interaction (PPI) data from 69 thereby restoring connectivity while preserving directionality of regulation. To enhance immediate readability and interpretability, we connected the resulting network with the corresponding cellular population abundances analyzed by cytometry in the samples. We thus extended the idea of matching expression profiles of master regulatory genes with cell types from50. These profiles being binary, they can be translated into Boolean functions, i.e. integrated directly into the network. We identified specific markers for each cellular population using the CellMarker70 and Human Protein Atlas 71 databases and linked them to the rest of the network through a disjunctive function of their markers. The resulting networks could be referred to as naïve, as they have been assembled from aggregated sources of knowledge generated in various experimental contexts and species, with different measurement technologies.
Modeled experimental data
The naïve Boolean networks describing vaccine-induced immune responses were calibrated using longitudinal in vivo datasets generated in NHPs. For the MVA-induced immune responses, we used data from 47. In this preclinical study, blood samples were collected from three cynomolgus macaques (Macaca fascicularis) at seven time points ranging from baseline (pre-vaccination) to one week after intradermal immunization. The sampling schedule included baseline, 3h, 6h, 24h, 48h, 72h, and 168h postadministration. Flow cytometry was performed to quantify immune cellular abundances and microarraybased transcriptomics to measure gene expression profiles on peripheral blood samples. On the other hand, the data used to calibrate the YF-17D vaccine-induced immune response model came from a separate cynomolgus macaque study described in 72. This dataset comprised blood samples from 12 animals collected at six time points: baseline and 1, 3, 7, 14, and 28 days after subcutaneous immunization. Samples were analyzed for immune cellular population abundances using mass cytometry, and gene expression levels were assessed using bulk RNA sequencing (RNA-Seq) transcriptomics. These two datasets provided time-resolved measurements of cellular and transcriptional responses, enabling the calibration of Boolean network dynamics to experimentally observed immune trajectories.
Context-specific calibration
To fine-tune naïve Boolean networks to the vaccine-specific contexts, we aligned them with experimental cellular abundance and gene expression data. We implemented a processing pipeline for these experimental data to suit the requirements of the Boolean formalism, converting continuous measurements into binarized time-series profiles. We filtered out the insufficiently strong signals, set a minimal fold change of 20% compared to baseline for at least one time point, and performed a Short Time-series Expression Miner (STEM) statistical filtering 73 with a threshold of 0.05 on the gene expression data. As cellular abundance data contained neither enough animals for classical statistical testing nor sufficient dimensionality for the STEM algorithm, they were manually evaluated and subjected to a classical 2-fold change filter. All data were binarized using a 2-means clustering strategy 74 on each expression/abundance profile. The resulting binarized data were then fed into the calibration algorithm named ZhegAlCal and presented in 75 along with the naïve Boolean networks. The ZhegAlCal tool was parametrized to look for the network that maximized the overlap between the successive states of its nodes and the provided binarized profiles, while allowing for at most one intermediate network state between time points and imposing a fixed-point attractor.
Boolean network analysis, target identification and perturbation
Boolean networks can be analyzed both as through the perspective of graphs theory or dynamic simulation. We therefore combined topological and dynamic analyses to identify regulatory nodes with strong system-wide impact and to evaluate candidate intervention targets.
To quantify the size and connectivity of Boolean networks, we measured their number of nodes, interactions, and conjunctive clauses in the network regulatory functions. As a first attempt to identify their dynamically relevant nodes, we extracted their hubs, as defined in 76. To refine this preliminary identification, we measured their Vertex Betweenness and Determinative Power, highlighted in 77 as being associated with a strong dynamic impact. To bridge the gap with the actual networks’ dynamics, we computed the activity and effective graphs introduced in 78 and 79. Both concepts are presented as hybrid static/dynamic representations: the activity from one node to another is the probability that a perturbation of the former causes a perturbation in the latter in the next state. Quite similarly, the effectivity from one node to another captures the extent to which an incoming edge from the regulatory node is, on average, necessary to determine the value of the regulated node. Interestingly, this second notion has been recognized as an alternative definition for collective canalization, itself a generalization of the concept of canalization introduced in 80 and shown to be inherent to a vast majority of biological processes 81. Based on these graphs, we implemented a search and display of the nodes that combined large numbers of output edges and high average activity/effectiveness, which we posited as being the variables with the strongest dynamic impact on their downstream nodes. We pushed the concept further as we then computed an algorithm to iteratively find the nodes with a large activity/effectiveness upstream of the identified nodes to define highly active or effective signal paths. These flows could indicate preferential targets to strongly affect the dynamics of a Boolean network.
Finally, we designed a workflow to perturb the Boolean networks by forcing a constant activation (on state) or inhibition (off state) onto a selected set of nodes suggested by the static analyses and comparison, and visualize the resulting changes in their dynamics. We additionally favored actionable target nodes through MVA genetic alterations. The changes are displayed as a downregulated vs. stable vs. upregulated heatmap from unperturbed to perturbed conditions. However, such a heatmap can be investigated in detail only for a limited number of nodes. To extend our analysis to a system-wide scale, we adapted Gene Ontology (GO) enrichment analysis 82 to our work. GO enrichment analysis is generally used to identify overrepresented terms in a gene set compared to a reference set, linking them to biological processes, molecular functions, and cellular components. For a Boolean network in a given state, we can extract the upregulated genes that went from off at baseline to on, or the downregulated genes that went from on to off and generate the resulting enriched GO terms; compared to all nodes in the network. In this work, we concentrated our analysis on biological processes using the 2023 Gene Ontology database 83 via the GSEApy Python library 84.
Results
The construction of Boolean models of vaccine-induced immune responses comprised several sequential steps. First, naïve Boolean networks were generated by converting and merging several signaling pathways into Boolean logic and enriching the resulting network with oriented protein-protein interactions and immune cellular populations. Context-specific experimental data were then provided as binarized time series and used to calibrate the naïve Boolean networks. The calibrated Boolean networks were subsequently simulated and analyzed to produce mechanistic insights and to identify and evaluate candidate perturbation targets. The complete workflow is described in Figure 1.

Workflow for the construction, calibration, and analysis of Boolean models of vaccine-induced immune responses combining prior knowledge and context-specific experimental data.
Schematic overview of the methodology used to integrate prior biological knowledge and context-specific experimental data into executable Boolean networks. The workflow illustrates successive steps to build a Boolean network combining existing knowledge from different sources and experimental data to construct a naïve Boolean network and calibrate it respectively, and to analyze it (both statically and dynamically after simulation) to gain mechanistic insights and identify and test perturbation targets. Boolean networks were visualized using the Living Map software (BIOVIA, Dassault Systèmes). Proteins are represented as blue rectangles and phenotypes or cellular populations as orange hexagons. The heatmap illustrates node states across successive network updates, with green indicating active (on/1) and red inactive (off/O) states.
Construction of a naïve Boolean network of the immune response to MVA
Although its cellular receptor remains unknown, MVA enters the cells similarly as VACV by direct fusion with the plasma membrane through a fusion complex or macropinocytosis 85,86, and preferentially infects antigen-presenting cells (APCs), such as DCs and macrophages 87–89. Upon infection, DCs can follow two main fates: activation through the cGAS/STING-mediated cytosolic DNA-sensing pathway, as shown in a murine model in 90 and confirmed in human DCs in 91, or cell death via apoptotic mechanisms. In addition, non-infected DCs can be indirectly activated through cytokine production by neighboring infected DCs 91. In murine and human macrophages, MVA infection triggers diverse apoptotic pathways 92,93 and activates the NF-κB pathway 92,94 Interestingly, the parental VACV strains Copenhagen 95 and Western Reserve (WR) 96 encode several intracellular immunomodulatory proteins that inhibit NF-κB signaling, such as A52 97 and N1 98, which are not conserved in the MVA genome. This difference could contribute to the observation that MVA, but not WR, activates NF-κB in human macrophages and fibroblasts 92. This previous knowledge was used to define the backbone of a representative naïve Boolean network, i.e. its topology or which nodes compose the network and how they interact. We merged the Cytosolic DNA-sensing (which includes type I interferon (IFN) signaling), apoptosis, and NF-κB signaling pathways from KEGG 68 into a single gene regulatory network using BIOVIA Living Map, a software on the Dassault Systèmes 3DEXPERIENCE platform (BIOVIA, Dassault Systèmes). These pathways encompass key mechanisms important in how MVA infects and is sensed by host cells, and thereby induces essential innate immune responses. In addition, NF-κB and type I IFN signaling also play a crucial role in amplifying these inflammatory and antiviral responses in both infected and uninfected (bystander) cells.
Network calibration with experimental datafrom a NHP immunogenicity study
To calibrate the naïve network, we used data from the preclinical study described in 47. Healthy adult male cynomolgus macaques (Macaca fascicularis) were immunized intradermally with a recombinant MVA expressing eGFP. The experimental data underwent preprocessing. In particular, we implemented a data filtering strategy compatible with datasets derived from small numbers of individuals. The resulting binarized time-series data were used as input to the ZhegAlCal calibration algorithm 75 together with the naïve Boolean network (Figure 1). ZhegAlCal was to identify the network configuration that maximized the overlap between successive node states and the corresponding binarized experimental profiles. Calibration allowed for at most one intermediate network state between consecutive experimental time points and imposed convergence toward a fixed-point attractor. The calibration Python script was run in less than one day on a Windows 10 workstation equipped with an 11th Gen Intel Core i7-11850H CPU (2.50 GHz) and 32 GB RAM.
Characterization of the calibrated Boolean network of the immune response to MVA
The calibrated Boolean network describing the innate immune response to the MVA vaccine in NHPs comprised 211 nodes, including 200 genes, proteins, or molecules from the Cytosolic DNA-sensing, apoptosis, and NF-κB signaling KEGG pathways, as well as 11 immune cellular populations. Nodes were regulated by up to 11 inputs. The network is illustrated in Supplementary Figure S1 and is available for simulation, perturbation, and analysis on the CellCollective platform. Each cell type was connected to the gene regulatory components of the network through logical functions based on gene markers obtained from CellMarker70 and the Human Protein Atlas 71.
To ensure that the calibrated Boolean network covered a broad spectrum of immune processes, we performed a static Gene Ontology (GO) enrichment analysis of the 200 genes derived from the three merged selected KEGG pathways using the human genome as reference (due to the lack of a cynomolgus macaque GO reference) (Figure 2). We observed a comprehensive overview of biological processes classically involved in responses to viral infection99. As expected, these included processes intrinsic to the NF-κB and apoptosis pathways. Importantly, enrichment also encompassed cytokine-related processes, particularly TNF signaling and production, as well as a broader inflammatory processes and alternative sensing pathways, supporting the ability of the calibrated network to capture systemic immune responses beyond infected APCs.

Broad description of the innate immune response to the MVA vaccine.
Top 25 Gene Ontology (GO) biological process terms identified by static GO enrichment analysis of the 200 genes included in the naïve Boolean network, compared to the human genome as reference. Dark grey bars correspond to processes intrinsic to the three constituent signaling pathways used to build the network (Cytosolic DNA-sensing, apoptosis, and NF-κB signaling KEGG pathways), whereas lighter grey bars indicate broader processes emerging from the integration of these pathways. The x-axis represents the negative logarithm of the associated p-values, all of which are below 0.05.
The dynamics of the simulated Boolean network for immune cellular populations are shown in Figure 3a. We employed synchronous update semantics to ensure deterministic trajectories between any successive states, which also tend to yield shorter and more interpretable trajectories while preserving essential information about the network 100. During calibration, intermediate states were introduced between certain experimental time points (between 24h-48h, 48h-72h, and 72h-168h) to maximize the overlap with the provided data. To evaluate the efficiency of the calibration process, faithfulness with the calibrated data was assessed by comparing the simulated profiles of the network nodes that appear in this data with their binarized experimental values (Figure 3b). We obtained satisfactory average ratios of correctly predicted states of 87% for the differentially expressed genes (not shown) and 86% for the differentially abundant cells (Figure 3c). To further evaluate the biological relevance and the comprehensiveness of the simulated trajectory of the Boolean network, we computed a GO enrichment analysis for the upregulated nodes for each one of its successive states after baseline. The enrichment results on the successive time points showed a broad response to the vaccine administration (Supplementary Figure S2). The GO terms that were upregulated after one update of the network covered a variety of processes without any clear trend. However, the next state, corresponding to 6h post-administration, highlighted a substantial activation of cellular migration processes, including chemotaxis, consistent with immune cell recruitment from the bone marrow to the vaccine injection site through the bloodstream, which is part of the inflammatory response 101. The subsequent state, associated with the 24h time point, showed strong enrichment of T cell-related processes, particularly T helper 1 responses, along with regulation of associated cytokines, such as IL-2, in agreement with observations reported in 47. After two additional updates, the Boolean network state reflected regulation of both innate and adaptive immune mechanisms, with prominent upregulation of host responses against viral and double-stranded RNA (dsRNA) stimuli. This aligns with dsRNA production during later phases of poxvirus replication 102, and with reports that a modified MVA strain producing excess dsRNA early during infection induces stronger innate immune response 103. The last four states of the trajectory maintained strong antiviral signatures and showed enrichment of hydrogen peroxide-related processes up to one week post-infection, suggesting sustained release of reactive oxygen species (ROS) to fight the infection. In contrast, decrease ROS production has been reported as an immune evasion mechanism of VACV 104,105.

Simulated MVA-induced cellular abundance trajectories compared with binarized experimental data.
(a) Simulated binary immune cell population abundances, (b) Experimentally measured and binarized cellular population abundances. In panels (a) and (b), heatmaps indicate node states across successive network updates or experimental time points, with green representing active/high (1) and red inactive/low (0) states. (c) Comparison of simulated and experimental binary states. The heatmap represents correctly predicted states in blue and incorrectly predicted states in dark grey. Light grey columns correspond to intermediary simulation steps that do not match an experimental sampling time point.
Overall, analysis of the unperturbed network dynamics confirmed that the calibrated Boolean network recapitulates the experimentally observed sequence of immune events induced by a parental MVA in the reference study 47 and in related contexts 106. These results support the ability of the Boolean formalism to qualitatively capture key features of the complex early vaccine-induced immune responses, in general and to MVA specifically as proof-of-concept, despite its inherent simplifications.
Challenging the Boolean network with vaccine mutations
To further validate the Boolean network of immune response to MVA and support its biological relevance and legitimize its use, we evaluated its predictive capacity under previously unseen conditions. We perturbed the system to mimic immunization with modified MVA vectors described in the literature to be more immunogenic than the parental MVA used to construct the model. The outcomes of these in silica perturbations were then compared with the corresponding experimental data.
The Boolean network we built and calibrated for our application is a model of the host immune responses and exclusively integrates host genes, proteins, and cellular populations, corresponding to an averaged representation of three animals. To mimic the alterations of the MVA genome that constitute our experimental references for validating the heterologous predictions, we needed to identify their major interactors within the host proteome in existing literature. Several mutant MVA vaccines with deletions in immunomodulatory genes, including A40R, A46R, C6L, K7R, and N2L, have been described and evaluated for replication and immunogenicity 23,25,26,28,29. The host targets of some of these viral proteins are well characterized. The C6 protein interacts with the TBK-1 adaptor proteins TANK, TBKBP1, and AZI2, thereby inhibiting IRF3 and IRF7 activation at the level of MAVS, IKBKE, and TBK1 107. The K7 protein also inhibits IRF3 and IRF7 activation via the IKBKE/TBK1 axis by binding DDX3X host protein and also suppresses TLR-induced NF-κB activation by its targeting of IRAK2 and TRAF6 108. Finally, the A46 protein interferes with IRFs, NF-κB, and MAPKs activation by sequestering adaptor proteins MYD88, TIRAP, TICAM1, and TICAM2 109, thereby preventing the assembly of MYD88 and TIRAP and stopping their signaling cascade 110. All of the aforementioned MVA-host interactions are inhibitory. Thus, deleting the given viral gene is expected to reduce the inhibitory effect of the corresponding viral protein. We mimicked this process by forcing the activation of target host genes in the Boolean network.
We next evaluated in silica immune responses to the triple mutant MVA AC6L/AK7R/AA46R and compared them with experimental data from in vitro and in vivo mouse studies using two recombinant MVA AC6L/AK7R/AA46R expressing Chikungunya and Ebola virus antigens 23,28. As readouts, we selected genes whose expression we had experimentally quantified in comparison to the unmutated parental MVA, including IFN-β (IFNB1), IL-6, TNF-γ (TNF), and CCL5 (RANTES) inflammatory cytokines and chemokines, as well as two IFN-stimulated genes (ISGs): the type I IFN-inducing cytosolic pattern recognition receptor RIG-I, and the chemokine IFN-γ-induced protein 10 IP-10 (CXCL10). We displayed the changes between the wild-type and triple-mutant MVA perturbed model dynamics in a downregulated (i.e., that went from 1 to 0) vs. stable vs. upregulated (that went from 0 to 1) heatmap for these selected genes and the network cellular populations (Figure 4a). The binary trajectories underlying this confrontation are given in Supplementary Figure S3. The perturbed model was obtained by forcing the activation of the following genes: TICAM1, TICAM2, TBK1, IKBKE, MAVS, TRAF6, and the MYD88:TIRAP complex, corresponding to the deletion of the three viral genes, all known to show inhibitory effects.

Perturbation of Boolean network trajectories in simulations of the triple mutant MVA ΔC6L/ΔK7R/ΔA46R compared with parental MVA.
(a) Detailed heatmap showing downregulated (white), stable (pink), and upregulated (dark red) nodes for immune cellular populations and selected innate immune marker genes. Perturbations correspond to the simulated deletion of the C6L, K7R, and A46R genes in the MVA genome relative to the parental MVA condition. (b) System-wide heatmap displaying downregulated, stable, and upregulated nodes for the same perturbations scenario compared with parental MVA.
We observed that the triple mutant MVA ΔC6L/ΔK7R/AA46R upregulated the expressions of IFN-β and of the proinflammatory cytokines IL-6 and TNF-α, as well as IP-10, consistent with enhanced inflammatory and innate responses. Cellular populations showed less drastic perturbations of their abundance. We saw an upregulation at earlier time points for plasmacytoid DCs (pDCs) and B cells, and at later time points for natural killer (NK) cells. Towards the end of the simulated trajectories, B cells and classical monocytes showed a downregulation, whereas MDSCs and granulocytes showed less intelligible fluctuations. Overall, these observations were concordant with the reported experimental phenotype of the mutant MVA-induced responses assessed in vitro using the human monocytic cell line THP-1, and in vivo in mice 23,28, particularly the early upregulation of IFN-β, TNF-α, and IL-6. The lack of perturbation we observed for RIG-I also aligned with experimental observations, unlike some of the changes we saw for IP-10 and, conversely, did not see for CCL5 (RANTES). It suggested that the Boolean network gave a credible description of the molecular and cellular innate mechanisms involved in these responses. To widen our investigation and look at the full Boolean network dynamics, we also displayed the system-wide downregulated vs. stable vs. upregulated heatmap, with all network nodes making up the y-axis (Figure 4b). This illustration highlighted the fact that few perturbations (in this case just 7) strongly affected the network behavior, in both permanent and transitory ways.
To provide a biological interpretation for these perturbations, we computed the GO enrichment analyses for the upregulated genes at each time point of the mutant MVA-induced dynamics (Supplementary Figure S4). By comparing, update-by-update, these GO enrichment results with the enrichments of the parental MVA-induced Boolean trajectory (Supplementary Figure S2), we noted a similar cascade of early events followed by a resembling, yet presumably broader (less T helper-oriented), T cell response, a longer-sustained upregulated acute inflammation, and an earlier antiviral response at 24h postadministration. The network states that led to the 48h time point translated a continuation of these features, thereby converging back to the unperturbed response. We could, however, observe an earlier upregulation of ROS secretion. Finally, the later network states in perturbed conditions closely resembled the unaltered dynamics despite a notably stronger downregulation of apoptotic processes.
Together, these network perturbation analyses demonstrated the predictive capacity of the Boolean model for MVA-induced immune responses, and support the validity of the modeling strategy. Next, we used the Boolean model of immune response to MVA to evaluate novel MVA mutants derived from expert knowledge.
Guiding the design of new mutant MVAs using the Boolean network
We next harnessed the Boolean model of the MVA-induced response to virtually evaluate two new mutant MVA vectors. VACV N2L (MVA021L) has been reported to encode a protein that inhibits IRF3 activation downstream of TBK1 after IRF3 translocation into the nucleus 111, and deletion of N2L from MVA has been associated with increased immunogenicity in mice 26. Using the Boolean model of MVA-induced response, we tested the effects of combining N2L deletion with deletions of C6L, K7R, and A46R by forcing IRF3 activation, in addition to activation of TICAM1, TICAM2, TBK1, IKBKE, MAVS, TRAF6, and the MYD88:TIRAP complex. Consistent with in vitro data obtained in THP-1 cells and monocyte-derived DCs 26, we observed a minor and transient change in IFNB1 behavior for the single N2L mutant compared to the wild-type MVA, but not of TNF. However, there was no effect on immune cell subset abundances (Figure 5a), nor was there a difference between the quadruple MVA ΔN2L/ΔC6L/ΔK7R/ΔA46R mutant and the triple MVA ΔC6L/ΔK7R/ΔA46R mutants when compared to the parental MVA (Figure 5b and Figure 4a).

Perturbations of Boolean network trajectories in simulations of the MVA ΔN2L and MVA A21L-F55A/T116A/T117A mutants and the corresponding quadruple mutants MVA ΔN2L/ΔC6L/ΔK7R/ΔA46R and MVA A21L-F55A/T116A/T117A/ΔC6L/ΔK7R/ΔA46R compared with parental MVA.
Detailed heatmaps showing downregulated (white), stable (pink), and upregulated (dark red) nodes for immune cellular populations and selected innate immune marker genes. Perturbations correspond to: (a) deletion of the N2Lgene; (b) deletion of N2L, C6L, K7R, and A46R genes; (c) alanine substitutions F55A/T116A/T117A in the A21L gene; and (d) the same alanine substitutions in the A21L gene combined with deletion of C6L, K7R, and A46R genes. All conditions are shown relative to the parental MVA simulation.
The MPXV OPG147 gene encodes a protein that has been shown to inhibit the cGAS-MITA/STING-mediated innate immunity by preventing its ISGylation, oligomerization and trafficking 112. This gene is conserved among poxviruses; VACWR140 (A21L) and MVA 131L are orthologs 21. Substitution of three alanines at positions 55, 116, and 117 of VACV A21L gene has been reported to maintain VACV competence for viral entry and virus-induced cell-to-cell fusion, while abrogating its interaction with MITA/STING1, resulting in enhanced innate immune responses compared with wild-type VACV in vitro (THP-1 cells) and in vivo in mice 112. To model this mutation, we activated MITA/STING1 in the Boolean model of the response to MVA to mimic immunization with an MVA A21L-F55A/T116A/T117A mutant. This perturbation alone led to transient IFNB 1 upregulation (like in mice) and increased pDC abundance compared with parental MVA (Figure 5c). However, the quadruple MVA A21L-F55A/T116A/T117A/ΔC6L/ΔK7R/ΔA46R mutant and the triple MVA ΔC6L/ΔK7R/ΔA46R mutant when compared to parental MVA did not differ qualitatively (Figure 5d and Figure 4a).
No qualitative differences were observed in silico between the triple MVA AC6L/AK7R/AA46R mutant and the two new quadruple MVA mutants (MVA ΔN2L/ΔC6L/ΔK7R/ΔA46R and MVA A21L-F55A/T116A/T117A/ΔC6L/ΔK7R/ΔA46R). However, the inherent limitations of Boolean modeling, which captures only binary state changes, prevent the capture of quantitative differences between them that could result from additive or synergistic effects of N2L deletion or alanine substitutions in A21L in combination with deletions of C6L, K7R and A46R. Given that not only the quality and dynamics of innate immune responses, but also their magnitude, modulate adaptive immune responses, the construction and in vitro and in vivo testing of these two new MVA quadruple mutants, identified using the Boolean model of response to MVA in a supervised, expert-guided manner, might still be worthwhile. Next, we investigated the potential of Boolean modeling for unsupervised rational discovery of additional MVA variants.
Improving MVA immunogenicity through comparison with the YF-17D-induced immune response
Construction of a consensus naïve network
To fully exploit the model of responses to MVA as a discovery tool to improve its immunogenicity, we compared it with a model of responses to YF-17D, one of the most successful vaccines developed to date. This comparison first required the construction of a shared naïve network between MVA and YF-17D.
The YF-17D vaccine has been shown to infect several DC subtypes, such as myeloid DCs (mDCs) and pDCs 38–44 Upon infection, these DCs signal through multiple Toll-like and RIG-I-like receptors41. Immature DCs undergo apoptosis upon infection, unlike mature DCs 38. Notably, the production of IFN-a by pDCs during YF-17D infection requires activation of the mTOR pathway, which is also necessary for optimal antigen-specific CD8 T-cell responses 113. Based on this literature-derived knowledge, we enriched the initial MVA-specific naïve Boolean network (constructed from 3 KEGG pathways) with the Toll-like receptor, RIG-I-like receptor, and mTOR signaling pathways, also obtained from KEGG 68 and imported into BIOVIA Living Map (BIOVIA, Dassault Systèmes). The resulting consensus naïve network recapitulated the main biological entities and mechanisms that characterize both MVA and YF-17D vaccine-induced innate immune responses.
Separate calibrations
Using this shared topology, MVA and YF17D vaccines-specific immune responses were defined through separate calibrations with dedicated preclinical datasets. For MVA-induced responses we used the gene expressions and cellular abundance data from 47, whereas for YF-17D-induced responses we used the gene expressions and cellular abundance data from a separate cynomolgus macaque study from 72. To maximize comparability, both networks were calibrated using only data from overlapping time points: baseline, 1 day, 3 days, and 1-week post-injection. The ZhegAlCal tool from75 was applied to the consensus naïve network and separately with the processed and binarized MVA and YF-17D datasets. It was parametrized to allow for at most one intermediate network state between experimental time points and to assume convergence to a steady-state attractor, consistent with the studied time scale. The respective Python calibration scripts were run in 12 and 37 hours for the MVA and YF-17D networks, respectively, on a Windows 10 workstation equipped with an 11th Gen Intel Core Î7-11850H CPU (2.50 GHz) and 32 GB RAM. Both calibrated Boolean networks are provided in Supplementary Figure S5 and are available on the CellCollective platform.
Comparative dynamics analysis
To compare the behavior of the MVA and YF-17D vaccine-induced response Boolean networks, we computed their dynamics and displayed binary trajectories of cellular abundances (Figure 6a and Figure 6d), the corresponding experimental binary profiles (Figures 6b and 6e), and their comparison (Figure 6c and Figure 6f). We saw that the calibration algorithm exploited the potential additional network update between experimental time points to better match the provided data. The MVA network included one additional state between 3- and 7-days post-injection, whereas the YF-17D network included two intermediate states, between 1 and 3 days and between 3 days and 1-week post-injection. The two models accurately recapitulated the experimental data used for calibration, correctly predicting the states of 92% and 86% of differentially expressed genes in the MVA and YF-17D networks, respectively (not shown), as well as 98% and 100% of differentially abundant cellular populations (Figure 6c and Figure 6f).

Comparison of simulated and experimental binary immune cell population dynamics following MVA and YF-17D vaccination.
Simulated binary immune cell population abundances ((a) and (d)), experimentally measured binarized cellular abundances ((b) and (e)), and comparison between simulated and experimental binary states ((c) and (f)) are shown for MVA- ((a), (b), and (c)) and YF-17D-induced ((d), (e) and (f)) immune responses. Heatmaps display node states as On (green, 1) or Off (red, 0) across network updates or experimental time points. In the comparison panels, correctly predicted states are shown in blue and incorrectly predicted states in dark grey. Light grey columns correspond to intermediary simulation steps that do not match experimental time points.
We performed a GO enrichment analysis for both vaccine-induced response networks at every state after baseline (Supplementary Figure S6). The successive states of the MVA response network translated an early (1-3 days post-injection) upregulation of calcium-related processes, STAT phosphorylation, and global downregulation of leucocyte apoptosis. The GO terms suggested a concentrated cytokine and chemokine environment that induced cellular migration, along with early regulation of T lymphocyte activation and antiviral processes. The later states still showed sustained T cell activation, cytokine and chemokine-related as well as antiviral processes. Yet, the response seemed to have become broader, with a transition toward adaptive immune mechanisms, including translated B cell differentiation, activation, and NK cell activity. The final state (1-week post-injection) expressed this broad response with a weaker antiviral response but enhanced IL-2 production. Overall, when enriched with three additional signaling pathways to cover a broader spectrum of MVA-inducible mechanisms (but still calibrated with the data from 47), the unperturbed response retained its properties. The GO terms associated with the trajectory followed by the YF-17D response network differed from that of MVA, as expected from experimental data 37. They showed strong metabolic activity and signaling through the NF-κB signaling pathway at 1 day post-injection. The following state revealed a broader response where the upregulated metabolic processes persisted alongside an enhanced T cell activity and PI3K-Akt signaling, as well as downregulated apoptotic processes. We also noticed the contribution of a type II IFN-mediated response. At 3 days post-injection, apoptotic processes remained downregulated. In addition, the GO terms indicated an important role for Fc receptor-induced signaling. The last two states translated substantial signaling through the MAPK pathway, intertwined with an enhanced response to stress. A variety of other phenomena were also observed one week after immunization with the YF-17D vaccine, including cellular antiviral processes, granulocyte chemotaxis, and a response to oxygen species that suggests ROS secretion.
Comparative static analysis
We next performed a static analysis of the two Boolean networks. Because the MVA and YF-17D datasets included different sets of filtered cellular populations, the MVA-induced response Boolean network had one additional cell-type node compared with the YF-17D network (Supplementary Figure S5) (329 vs. 328 total nodes). The MVA network also had 2 more interactions and 5 more conjunctive clauses that connected these cellular populations to the rest of the nodes. Interestingly, this difference did not extend to the full calibrated networks. Indeed, the YF-17D-induced response network exhibited a larger number of interactions and conjunctive clauses (583 and 509, respectively) compared with the MVA network (576 and 481, respectively).
Moving on to the graph theory measures, both networks had the same hub nodes (as defined in76): FOS, GZMB, IRF3, IRF5, MTOR, NFKB1, NFKB1:RELA, TP53, TRAF2, and TRAF6. The refined Determinative Power (DP) and Vertex Betweenness (VB) metrics were confronted for the MVA- and YF-17D-induced responses network (Figure 7a and Figure 7b). We annotated the dots corresponding to the nodes that displayed high VB and DP. Both networks also attributed high VB and DP to the same node, AKT3. In addition, this analysis highlighted the shared importance of the RELB:NFKB2 complex and the INSR, TNFRSF1A, RPS6KB1, PIK3CA, and MAP3K7 nodes. We computed the effective graphs 79 of the MVA and YF-17D-induced response Boolean networks. We then displayed the average effectiveness of their nodes as a function of the number of output edges (Figure 7c and Figure 7d). We annotated the dots that combined large numbers of output edges and high average effectiveness. Once again, the highlighted nodes for both MVA and YF17D vaccine-induced networks aligned with their hubs, with the additional node RELB:NFKB2. We also noted the presence of CD14 among them for the MVA-induced response, which could be a bias due to the large number of monocyte populations that are connected to this marker. Finally, as in 79, we measured the average effectiveness of the regulatory functions in both Boolean networks as a function of their number of input variables (Figure 7e). We obtained values that aligned with what is presented in 79 for Boolean networks stored on the CellCollective repository, and that were substantially smaller than for randomly generated networks. According to the authors, this reduced effectivity implies collective canalization, which is an indicator of robustness to perturbations and a property shared by most real biological systems.

Static analysis of the MVA- and YF-17D-induced immune response Boolean networks.
(a-b) Determinative Power (DP) vs. Vertex Betweenness (VB), reflecting node connectivity, for the MVA-induced (black, a) and YF-17D-induced (yellow, b) immune responses. Nodes with high DP and VB values are annotated, (c-d) Average effectiveness vs. number of outgoing edges, for the MVA-induced (black, c) and YF-17D-induced (yellow, d) immune responses. Nodes combining high average effectivity and large numbers of outgoing edges are annotated, Minimal values for annotation are represented as a red line. (e) Average effectiveness of regulatory functions in both networks as a function of the number of input variables (k). (f) Highly effective signaling paths (with relative effectiveness (→) > 0.6) leading to dynamically impactful nodes (in bold), defined as nodes with the highest connectivity (DP vs. VB), and average effectiveness. Blue boxes highlight host targets of immunomodulatory MVA genes previously described in the literature.
MVA-induced immune response improvement via Boolean network comparison
Both the cellular population dynamics (Figure 6a and Figure 6b) and the GO enrichment analyses of system-wide network states (Supplementary Figure S6) showed major differences in how the hosts (cynomolgus macaques here) respond to the MVA and YF-17D vaccines, as expected. An overview of these differences indicated a less extensive, or potentially delayed, adaptive response in favor of innate immune mechanisms and stress-induced MAPK signaling for YF-17D, as previously described 37. Yet, vaccine optimization has proven to be a subtle procedure, and the dissimilarity between the modeled responses was not specific and precise enough to point out a clear improvement strategy straightforwardly. Next, we investigated which components of this complex system could best be affected to orient the response in the desired direction, and how to do so.
Building on the identification of dynamically impactful network nodes, we developed an automated tool to find highly effective signal paths leading to these nodes. Nodes within these paths were conjectured to influence the network dynamics when targeted, as their perturbation significantly affects the state of their downstream nodes toward one or more of the identified dynamically impactful nodes, which, in turn, powerfully impact the entire network. We computed the highly effective paths leading to the nodes of interest identified and annotated in Figure 7c (Figure 7f). Historically, two strategies have been used to improve MVA viral vaccine vectors: the insertion of exogenous co-stimulatory molecules into the MVA genome and the deletion of some of its remaining immunomodulatory genes22. The overlap between tested co-stimulatory molecules, cytokines, and chemokines (IL-2, IL-12, and IL-15, IFN-γ, OX40/OX40L, a triad of B7-1, ICAM-1, and LFA-3 molecules, a triad of CD80, CD86, and CD83 molecules, CD40L, or GM-CSF) and the nodes included in at least one effective path yielded no results. On the other hand, many of the tested poxvirus deletions have been shown to affect host genes within these paths. After filtering out the deletions concerning viral genes that are not conserved in the MVA genome (which differs distinctly from the VACV it originated from 21), we intersected the host interactors of the remaining viral genes with the nodes in the highly effective paths. The matching nodes in the host response network are CHUK, IKBKB, MAVS, NFKBIA, TRAF6, and ZBP1. These are antagonized by proteins encoded by B14R, C6L, K1L, K7R, and E3L viral genes, respectively. In addition, the viral poxvirus gene F17R, which is conserved in the MVA genome 21, encodes the F17 protein recently shown to impair MTOR signaling upon infection 114. On the other hand, despite being (at least partially) conserved in the MVA genome, the functional integrity of the K1L gene, and therefore the effect of the K1 protein on the NFKBIA host gene, is unknown. We thus simulated the immunization with mutant MVA viral vectors with deletions in B14R, C6L, K7R, E3L, or F17R, which have never been considered, designed, constructed and evaluated on their own so far, to our knowledge. As all five viral proteins are inhibitors of the associated processes, we mimicked their deletion by a forced activation of their interactors. To evaluate the changes in the resulting network dynamics, we computed their downregulated vs. stable vs. upregulated heatmap between unperturbed (parental MVA) and perturbed (new mutants) conditions. In addition to the cellular populations, we highlighted the perturbations of genes involved in the induction or function of the stress-related JNK and p38 MAPK pathways, which are involved in the response to YF-17D. These include the IL-α (IL1B), TNF-α (TNF), and their receptors (IL1R1, TNFRSF1A), as well as the MAPK kinases MKK3 (MAP2K3) and MKK7 (MAP2K7), the MAPK kinases kinases MEKK1 (MAP3K1), ASK1 (MAP3K5), and TAK1 (MAP3K7), and finally the actual JNK1 (MAPK8) and p38α (MAPK14) genes. We also added the SIN1 (MAPKAP1) gene that is part of the mTORC2 complex, thereby bridging the gap between the stress-related MAPK and mTOR pathways, with the latter being an essential component of the YF-17D vaccine-induced response 113. We observed no noticeable changes for the ΔB14R, ΔC6L, and ΔE3L simulations (data not shown), in contrast to ΔK7R and ΔF17R MVA mutants’ trajectories (Figure 8a and Figure 8b). The binary trajectories underlying these latter comparisons are given in Supplementary Figure S7. The perturbations corresponding to the K7R deletion in MVA induced a slight decrease in NK and CD8 T cells at 1week postinjection. Interestingly, we also observed an increase in IL-1 β (logically followed by its receptor) and MAP3K1 that could respectively initiate and contribute to the JNK MAPK pathway (KEGG PATHWAY: MAPK signaling pathway - Homo sapiens). On the other hand, the perturbations corresponding to the F17R deletion in MVA provoked an upregulation of MAPKAP1 at later time points. In conclusion, we have demonstrated that our model construction and analysis strategy is a powerful tool for identifying new vaccine candidates, here two new recombinant MVAs that warrant further characterization, on their own as single mutant or combined with other deleted viral genes.

Simulated strategies for improving MVA viral vaccine vectors.
Dynamic simulation of immune cellular populations and stress-related MAPK marker genes following in silico deletion of the K7R (a) and F17R (b) genes from the MVA viral genome. Heatmaps represent downregulated (white), stable (pink), and upregulated (dark red) cell abundance or gene expression compared with the parental MVA.
Discussion
We previously designed and implemented a methodology to build and analyze large Boolean networks 75. We merge signaling pathways to form a naïve network with up to several hundreds of nodes and use a calibration tool that successfully aligns such a naïve network with context-specific experimental data. Here, we applied this methodology to provide mechanistic insights and vaccine improvement strategies with the virtual design and evaluation of new vaccine candidates. We used a preclinical trial with MVA as proof of concept. We first validated the methodology against experimental observations. The calibrated MVA-induced response network recapitulated experimental characteristics. We then validated the model and the modeling methodology through network perturbation. Its predictive capabilities were confirmed, as its simulation recapitulated the immunogenicity of a previously-reported mutant MVA vaccine, without the corresponding experimental data being used to construct the model. We finally exploited networks to uncover new vaccine strategies. New candidate mutant MVA vaccines were discovered by a rational design based on Boolean models and evaluated virtually. We tested deletions or point mutations of viral immunomodulatory genes derived from two sources: previous knowledge of host/poxviruses interactions on the one hand, and mechanistic insights gained from the analysis of the models on the other. We successfully perturbed the MVA input signal to mimic the YF-17D-induced immune response by identifying MVA-induced signaling paths with high dynamic impact. Therefore, Boolean modeling of immune responses to vaccines appears to be a useful and powerful tool for accelerating vaccine development by enabling the discovery, tailoring, testing, and ranking of new vaccine candidates to be further evaluated in vitro and in vivo.
Keeping in mind that the choice of the pathways that compose the naïve network is of paramount importance, as the biological entities they contain should allow for an exhaustive yet adequately specific description of the underlying phenomena, we built our initial Boolean model of the innate immune response to the MVA vaccine around three signaling pathways, mainly involved in detecting and initiating the immune response to viral stimuli. Nevertheless, the scope of the integrated KEGG NF-κB pathway simultaneously provides the necessary elements to depict the various immune, particularly inflammatory, processes occurring beyond infected cells. Overall, the static GO enrichment performed on its nodes showed a satisfactory balance between specificity and exhaustivity for describing MVA-induced immune responses. Moreover, the calibration process successfully overlapped its trajectory with longitudinal binarized experimental measurements. The comprehensive structure combined with the efficient calibration yielded a Boolean network whose successive states represented a series of biologically relevant and experimentally assessed processes106.
Simulating this network in perturbed conditions induced systemic modifications that strongly affected the network, and specifically the selected output markers (immune cell subsets abundance). The triple mutant MVA ΔC6L/ΔK7R/ΔA46R, modelled through the forced activation of the few host genes whose proteins have been reported to be inhibited by the C6, K7 and A46 viral proteins, notably induced changes over the entire network. These perturbations highlight an overall broader T-cell response, an upregulated acute inflammation, earlier upregulation of virus-induced innate immune responses and ROS secretion, and a downregulation of apoptosis-related processes at later time points, compared to the parental MVA. Such enhanced innate immune response that manifested through these virtual perturbations, particularly the early upregulation of IFN-β, TNF-α, and IL6, matched experimental data from 23,28.
Finally, we added three more KEGG pathways to the naïve network to obtain a consensus basis for both the MVA and YF-17D vaccines-induced responses Boolean networks. Together, the six pathways provided the necessary information for describing the variety of processes involved in the immune response to these live-attenuated vaccines. The static GO enrichment on the gene regulatory network resulting from the merger of the six pathways showed that these processes include mechanisms ensuing directly from the selected pathways, as expected, but also broader transversal phenomena such as inflammation and the production and response to a variety of cytokines, including TNF-α. An extensive analysis of the topological properties of both networks revealed a close resemblance. A slight difference, however, that could provide some insights into what causes the observed responses to differ, is the number of interactions, which is higher in the YF-17D-induced response network. This translated a stronger connectivity within the network, but could also imply a higher redundancy in the paths from one variable to its downstream nodes. Redundancy is generally associated with robustness but also with collective canalization 79. Collective canalization implies that a subset of the input variables for every regulatory function governs its output. In79, the authors also present the notion of effectiveness and associate it with collective canalization. We computed the effective graph for the MVA and YF-17D networks. We observed values that were, on average, substantially smaller than what is displayed by randomly designed networks, suggesting biologically relevant regulatory rules in both networks, as well as an overall tendency to robustly withstand perturbation. In this context, the numerous system-wide changes observed when forcing the activation of just a few nodes in the initial MVA Boolean network suggest that this model (and our underlying construction methodology) grasps the biological relevance of these immunomodulatory genes. Coming back to the MVA and YF-17D network comparison, we additionally note that the average effectivity was always smaller for the YF-17D-induced response network (except for 7-input functions), corroborating the slightly higher redundancy observed for this network.
The respective network trajectories, on the other hand, could hardly be more different. We observed almost opposite behaviors for several essential cellular populations present in both networks, such as (classical) monocytes, B cells, NK cells, CD4 and CD8 T cells. The successive GO enrichment analyses confirmed these observations, as the computed terms for all time points after baseline translated different biological processes. The successive MVA network states described a standard immune response, with early innate and inflammatory mechanisms that induced and guided an adaptive response before slowly fading away to leave only the adaptive processes. The trajectory followed by the YF-17D network, on the other hand, yielded less intuitive GO terms. Overall, we observed a response that was initiated by signaling through the NF-κB and Pl3K-Akt pathways, which then involved a variety of mostly innate immune mechanisms, even towards later time points and up to the final time point in this study at 1-week postinjection. Adaptive immunity processes remained notably scarce over the entire trajectory within this short timeframe. Interestingly, this observation overlaps with what is described in 37 where the transcriptional signature of the yellow fever vaccine YF-17D was compared with the signatures of 12 other vaccines, including a poxvirus-based smallpox vaccine (VACV, not MVA) and a recombinant MVA against tuberculosis. They also exhibited a delayed immune response, with antiviral processesjust starting at 3 days post-injection and reaching their peak after 1 week, which was also the only time point where the differential enrichment of the inflammatory processes was statistically significant.
Despite the differences between the MVA and YF-17D-induced responses and corresponding networks, no clear optimization strategies for the MVA viral vector came to mind from the comparison. We looked for components we could efficiently affect. We computed the highly effective signal paths that gave us the nodes most likely to strongly impact the network dynamics. We overlapped these nodes with the host genes known to interact with MVA viral genes. Among these viral genes, we found B14R, C6L, K7R, E3L, and F17R to possess interactors within our highly effective paths. The first four are known and their single deletions from poxviral genomes have been tested with optimization of their immunogenicity in mind 115. The last one, F17R, has only relatively recently been linked with an inhibitory effect on the mTOR signaling pathway, which immediately stimulated our interest, given the preponderant role of this pathway in the YF-17D response. We thus computed the perturbed responses mimicking a deletion in each one of the genes. Whereas the ΔB14R, ΔC6L, and ΔE3L simulations yielded no sensible observations, the deletion of K7R, and F17R to a lesser extent, showed interesting consequences. We noted higher levels of IL-1β and MAP3K1, which is involved in the stress-induced JNK MAPK pathway, for the former and slightly higher MAPKAP1 for the latter, which suggests an enhanced cross-activity with the mTOR pathway.
In truth, several aspects of our methodology could be improved and should perfect its outcomes. An important limitation of this study might be the Boolean approximation itself. Evidently, not all biological processes, especially gene expressions and cellular abundances, can realistically be described as on/off switches. This strong approximation can dilute subtle changes in larger trends, which might be what prevented us from observing more differences between the different perturbation scenarios. More generally, differences in the magnitude of observed phenomena can hardly be distinguished. To still capture as much biologically relevant information as possible, the data processing and binarization steps are of paramount importance. Notably, the 2-means clustering we employed here implies that an identical expression value in two different conditions can be assigned to either cluster depending on the other values. Again, this could explain why such little changes occurred between some scenarios and why some observations slightly diverged from experimental reality. Substantial improvement could be provided by a shift from Boolean to ternary 116 or multivalued 117,118 logic. Another refinement could be provided by changing not the number of potential states but the way they are updated. Examples include the addition of probabilistic activation and inhibition rates 119, or the application of the Most Permissive Boolean Network semantics 120.
Another vital parameter in our approach is what we use to build the networks. First, the knowledge we use as the backbone of these networks is of paramount importance. Despite its satisfactory coverage of the biological phenomena involved in the innate immune response to the MVA vaccine, the choice of signaling pathways to compose the naïve network admittedly skews the final model and the conclusions that can be drawn from it. Indeed, the Boolean networks of the MVA-induced immune response, calibrated with the same dataset but based either on a 3 - or 6-pathway naïve network backbone yield similar yet not identical simulated behaviors. In addition, as we remain limited in the number of pathways to add to our network backbone (mainly for computational reasons), some processes, but also relevant markers such as the macrophage inflammatory proteins (MIP) or IFIT1/2 highlighted in 23,25,28 are missing from both networks. Regarding the networks’ calibration, it allows for at most one computational state between measured time points. As the gaps between time points become larger (between 72 hours and 1 week for example), the freedom to incorporate more intermediate updates might be beneficial. However, they should be implemented carefully, considering the increased computation runtimes they imply. Furthermore, the nature of the data themselves and what they represent are of paramount importance in the Boolean network construction process. The study we used to provide the calibration data for the MVA-induced response network also contains cytokine concentration data, as well as antibody and T cell responses data 47, which we could use in the future to enable our modeling approach to predict and interpret immune mechanisms more explicitly. We also limited our modeling efforts to gene expression and cell abundances in the blood. To broaden its scope and provide a more complex overview of the vaccine-induced responses, modeling the same parameters in lymphoid organs and other tissues, especially in the vicinity of the vaccine administration site, would be beneficial. These compartments could be interconnected within a single Boolean network or an agent-based modeling framework, as respectively illustrated for multi-cellular models in 121 and 122.
In order to validate such developments, increasingly rigorous evaluation efforts should be undertaken. A key challenge lies in the nature of the validation data itself. In therapeutics design, specifically for applications in oncology, increasing resources regarding “perturbomics”, i.e. the systematic perturbation of biological systems, provide a way to map cellular responses to stimuli and help refine predictive therapeutic models 123,124. These perturbations, often chemical or genetic, are relatively straightforward to induce and measure, especially in vitro. In contrast, vaccinology presents a more complex landscape with immune responses that are local and systemic, which makes them difficult to replicate accurately outside of living organisms. Here, we leveraged the fact that mutant poxviruses have been extensively studied as vaccine vectors 22, often in a preclinical setting. A virtual evaluation of the use of pharmacological agents for host-targeted therapies, ideally stemming from drug repositioning 125 together with MVA, as a strategy to enhance its immunogenicity or to model immune responses in groups of treated patients to personalize vaccines, could also be conducted. Ideally, simulated and experimentally perturbed responses should be integrated within a single study to strengthen the legitimacy of the modeling approach. This could be seen as the start of an iterative circle of model refinement and empirical validation, where each cycle enhances both the predictive power and biological relevance of the system. In this framework, simulations help generate hypotheses about immune dynamics, which can then be tested through targeted perturbations. The resulting data not only confirm or refute the model’s predictions but also feed back into the simulation pipeline, allowing for a recalibration of the model. Over time, this virtuous cyclic approach should give a deeper mechanistic understanding of vaccine-induced immunity, bridging the gap between in silica simulation and in vivo complexity. Moreover, this iterative cycle lays the groundwork for the emergence of digital twin technologies in vaccinology. Originally rooted in engineering, a digital twin refers to a virtual replica of a physical object or system, continuously updated with real-time data to mirror its behavior. Therefore, we argue that a sufficiently detailed and up-to-date computational model can serve as a digital twin of a biological process. Boolean modeling, notably, has proven particularly effective for precise and even individualized simulations 65,126,127. Whereas emerging applications based on such a framework include personalized drug development and treatment optimization 128–13°, we believe similar advances could be brought to the fields of vaccine design and optimization.
Supplementary figures

Calibrated Boolean network of the MVA-induced immune response.
The network backbone is composed of the following three pathways from the KEGG database: cytosolic DNA-sensing, apoptosis, and NF-κB signaling. The naïve network was calibrated with experimental preclinical data from 46, using ZhegAlCal 74. The calibrated network is visualized using Dassault Systèmes Living Map software and is also available for simulation, perturbation, and analysis on the CellCollective platform (MVA 3 pathways).



Dynamic Gene Ontology (GO) enrichment analysis for the unperturbed MVA-induced innate immune response Boolean network trajectory.
The y-axis indicates the top 10 enriched biological process GO terms, while the x-axis displays the negative logarithm of the associated p-values (all < 0.05).

Binary cellular abundances and innate immune marker gene expressions in perturbed and unperturbed MVA-induced immune response Boolean network simulations.
(a) Parental MVA simulation. (b) Triple mutant MVA ΔC6L/ΔK7R/ΔA46R simulation.



Dynamic Gene Ontology enrichment analysis of the perturbed ΔC6L/ΔK7R/ΔA46R MVA-induced innate immune response Boolean network trajectory.
The y-axis indicates the top 10 enriched biological process GO terms, and the x-axis displays the negative logarithm of the associated p-values (all < 0.05).

Calibrated Boolean networks of the MVA- and YF-17D-induced immune responses.
The network backbone is composed of the following six pathways from the KEGG database: cytosolic DNA-sensing, apoptosis, Toll-like receptor signaling, RIG-I-like receptor signaling, NF-κB signaling and mTOR. The shared consensus naïve network was calibrated with experimental preclinical data from 46 and 71, and using ZhegAlCal74. The calibrated networks are visualized using Dassault Systèmes Living Map software and are also available for simulation, perturbation, and analysis on the CellCollective platform. (a) MVA-induced response Boolean network (MVA 6 pathways). (b) YF-17D-induced response Boolean network (YF17D).



Dynamic Gene Ontology enrichment analysis of the unperturbed MVA- and YF-17D-induced immune response Boolean network trajectories.
(a) MVA-induced response Boolean network. (b) YF-17D-induced response Boolean network. The y-axis indicates the top 10 enriched biological process GO terms and the x-axis displays the negative logarithm of the associated p-values (all < 0.05).

Binary cellular abundances and innate immune marker gene expression in perturbed and unperturbed MVA-induced immune response Boolean network simulations.
(a) Parental MVA, (b) MVA ΔK7R MVA, and (c) MVA ΔF17R simulations.
Data availability
Data complies with FAIR principles. Our findings could not have been be achieved without a computational tool we previously developed and published to model complex biological systems (doi: 10.1109/TCBB.2024.3456302), and we made the boolean models available for simulation, perturbation, and analysis on the CellCollective platform, a public deposition and execution environment.
Acknowledgements
We thank Nathalie Mantel (Vaccine Research and Development, Sanofi, Marcy 1’Etoile, France); Pierre Rosenbaum, Nicolas Tchitchek, Frédéric Martinon, and Roger Le Grand (IDMIT), Maria Chanzy (Dassault Systèmes) and Lina Cheraitia (IDMIT and Dassault Systèmes) for the valuable discussions.
Additional information
Funding
This work was supported by the Region Ile-De-France through the 2021 Paris Region PhD Program and Dassault Systèmes (for VD). The IDMIT infrastructure has been supported by the Programme Investissements d’Avenir (PIA), managed by the ANR under reference ANR-11-INBS-0008. The YF17D NHP study has received support from the Innovative Medicines Initiative Joint Undertaking (Biomarkers For Enhanced Vaccine Safety (BioVacSafe), IMI JU Grant Agreement no. 115308), resources of which are composed of financial contributions from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies in kind contribution.
Author contributions
Original draft writing: VD; Conceptualization: VD, PC, MC, LN, ASB; Methodology: VD, PC, MC, LN, ASB; Review, editing, and approval: VD, PC, JGA, ME, MC, LN, ASB; Supervision: PC, MC, LN, ASB; Funding acquisition: PC, MC, LN, ASB.
Funding
Region Ile de France (2021 Paris Region PhD Program)
Marine Ciantar
Anne-Sophie Beignon
Laurent Naudin
Philippe Castera
Vincent Deman
References
- 1.Efficacy of modified-vaccinia Ankara vaccine as pre- and post-exposure prophylaxis against monkeypox sexual transmission in non-human primate modelNat. Commun. 16:7306https://doi.org/10.1038/s41467-025-62681-2PubMedGoogle Scholar
- 2.Mpox Clinical Presentation, Diagnostic Approaches, and Treatment Strategies: A ReviewJAMA 332:1652–1662https://doi.org/10.1001/jama.2024.21091PubMedGoogle Scholar
- 3.Characterization and comparison of immunity against MPXV for individuals infected with MPXV or vaccinated with modified vaccinia Ankara vaccinesJ. Immunol. 214:211222https://doi.org/10.1093/jimmun/vkae031PubMedGoogle Scholar
- 4.Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and TanzaniaJ. Infect. Dis. 220:46–56https://doi.org/10.1093/infdis/jiz070PubMedGoogle Scholar
- 5.Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and ApplicationsVaccines 10:1516https://doi.org/10.3390/vaccines10091516PubMedGoogle Scholar
- 6.Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectivesfor Vaccine DevelopmentAdv. Virus Res. 97:187–243https://doi.org/10.1016/bs.aivir.2016.07.001PubMedGoogle Scholar
- 7.Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral DiseasesJ. Mol. Biol. 435:168173https://doi.org/10.1016/j.jmb.2023.168173PubMedGoogle Scholar
- 8.One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox VaccinesJ. Infect. Dis. 227:1203–1213https://doi.org/10.1093/infdis/jiac455PubMedGoogle Scholar
- 9.Orthopoxvirus-specific antibodies wane to undetectable levels 1 year after MVA-BN vaccination of at-risk individuals, the Netherlands, 2022 to 2023Eurosurveillance 29:2400575https://doi.org/10.2807/1560-7917.es.2024.29.38.2400575PubMedGoogle Scholar
- 10.MVA-BN vaccine effectiveness: A systematic review of real-world evidence in outbreak settingsVaccine 42:126409https://doi.org/10.1016/j.vaccine.2024.126409PubMedGoogle Scholar
- 11.Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against SmallpoxN. Engl. J. Med. 381:1897–1908https://doi.org/10.1056/nejmoa1817307PubMedGoogle Scholar
- 12.Control of adaptive immunity by the innate immune systemNat. Immunol. 16:343–353https://doi.org/10.1038/ni.3123PubMedGoogle Scholar
- 13.Immunological mechanisms of vaccinationNat. Immunol. 12:509–517https://doi.org/10.1038/ni.2039PubMedGoogle Scholar
- 14.From Vaccines to Memory and BackImmunity 33:451–463https://doi.org/10.1016/j.immuni.2010.10.008PubMedGoogle Scholar
- 15.Original Encounter with Antigen Determines Antigen-Presenting Cell Imprinting of the Quality of the Immune Response in MicePLOS One 4:e8159https://doi.org/10.1371/journal.pone.0008159PubMedGoogle Scholar
- 16.Vaccine Inoculation Route Modulates Early Immunity and Consequently Antigen-Specific Immune ResponseFront. Immunol. 12:645210https://doi.org/10.3389/fimmu.2021.645210PubMedGoogle Scholar
- 17.Immunogenicity of MVA-BN vaccine deployed as mpox prophylaxis: a prospective, single-centre, cohort study and analysis of transcriptomic predictors of responseLancet Microbe 6https://doi.org/10.1016/j.lanmic.2024.101045PubMedGoogle Scholar
- 18.Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypoxNature 428:182–185https://doi.org/10.1038/nature02331PubMedGoogle Scholar
- 19.The two-dose MVA-BN mpox vaccine induces a nondurable and low avidity MPXV-specific antibody responseJ. Virol. 0:e00253-25https://doi.org/10.1128/jvi.00253-25PubMedGoogle Scholar
- 20.Short-Lived Neutralizing Antibody Responses to Monkeypox Virus in Smallpox Vaccine-Naïve Persons after JYNNEOS VaccinationEmerg. Infect. Dis. 31:237–245https://doi.org/10.3201/eid3102.241300PubMedGoogle Scholar
- 21.The Complete Genomic Sequence of the Modified Vaccinia Ankara Strain: Comparison with Other OrthopoxvirusesVirology 244:365–396https://doi.org/10.1006/viro.1998.9123PubMedGoogle Scholar
- 22.Enhancing poxvirus vectors vaccine immunogenicityHum. Vaccines Immunother. 10:2235–2244https://doi.org/10.4161/hv.28974PubMedGoogle Scholar
- 23.A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infectionJ. Virol. 88:3527–3547https://doi.org/10.1128/jvi.03418-13PubMedGoogle Scholar
- 24.A Candidate HIV/AIDS Vaccine (MVA-B) Lacking Vaccinia Virus Gene C6L Enhances Memory HIV-1-Specific T-Cell ResponsesPLoS ONE 6:e24244https://doi.org/10.1371/journal.pone.0024244PubMedGoogle Scholar
- 25.Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling PathwaysPloS One 8:e66894https://doi.org/10.1371/journal.pone.0066894PubMedGoogle Scholar
- 26.Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus AnkaraexpressingHIV-1 antigensJ. Virol. 88:3392–3410https://doi.org/10.1128/jvi.02723-13PubMedGoogle Scholar
- 27.Deletion of A44L, A46R and C12L Vaccinia Virus Genes from the MVA Genome Improved the Vector Immunogenicity by Modifying the Innate Immune Response Generating Enhanced and Optimized Specific T-Cell ResponsesViruses 8:139https://doi.org/10.3390/v8050139PubMedGoogle Scholar
- 28.Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 ProteinsJ. Virol. 92:e00363-18https://doi.org/10.1128/jvi.00363-18PubMedGoogle Scholar
- 29.Deletion of Vaccinia Virus A40R Gene Improves the Immunogenicity of the HIV-1 Vaccine Candidate MVA-BVaccines 8:70https://doi.org/10.3390/vaccines8010070PubMedGoogle Scholar
- 30.Systems vaccinology: Enabling rational vaccine design with systems biological approachesVaccine 33:5294–5301https://doi.org/10.1016/j.vaccine.2015.03.072PubMedGoogle Scholar
- 31.A Single 17D Yellow Fever Vaccination Provides Lifelong Immunity; Characterization of Yellow-Fever-Specific Neutralizing Antibody and T-Cell Responses after VaccinationPLOS One 11:e0149871https://doi.org/10.1371/journal.pone.0149871PubMedGoogle Scholar
- 32.Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinologyNat. Rev. Immunol. 9:741–747https://doi.org/10.1038/nri2629PubMedGoogle Scholar
- 33.Metabolic perturbations and cellular stress underpin susceptibility to symptomatic live-attenuated yellow fever infectionNat. Med. 25:1218–1224https://doi.org/10.1038/s41591-019-0510-7PubMedGoogle Scholar
- 34.A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D VaccineJ. Immunol. 199:1476–1489https://doi.org/10.4049/jimmunol.1700083PubMedGoogle Scholar
- 35.Vaccine-induced T cell responses control Orthoflavivirus challenge infection without neutralizing antibodies in humansNat. Microbiol. 10:374–387https://doi.org/10.1038/s41564-024-01903-7PubMedGoogle Scholar
- 36.Systems biology approach predicts immunogenicity of the yellow fever vaccine in humansNat. Immunol. 10:116–125https://doi.org/10.1038/ni.1688PubMedGoogle Scholar
- 37.Transcriptional atlas of the human immune response to 13 vaccines reveals a common predictor of vaccine-induced antibody responsesNat. Immunol. 23:1788–1798https://doi.org/10.1038/s41590-022-01328-6PubMedGoogle Scholar
- 38.Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopesJ. Exp. Med. 202:1179–1184https://doi.org/10.1084/jem.20051352PubMedGoogle Scholar
- 39.Characterization of Yellow Fever Virus Infection of Human and Non-human Primate Antigen Presenting Cells and Their Interaction with CD4+ T CellsPLoSNegl. Trop. Dis. 10:e0004709https://doi.org/10.1371/journal.pntd.0004709PubMedGoogle Scholar
- 40.Mitochondrial hyperactivity and reactive oxygen species drive innate immunity to the yellow fever virus-17D live-attenuated vaccinePLoSPathog. 21:e1012561https://doi.org/10.1371/journal.ppat.1012561PubMedGoogle Scholar
- 41.Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunityJ. Exp. Med. 203:413–424https://doi.org/10.1084/jem.20051720PubMedGoogle Scholar
- 42.Immature particles and capsid-free viral RNA produced by Yellow fever virus-infected cells stimulate plasmacytoid dendritic cells to secrete interferonsSci. Rep. 8:10889https://doi.org/10.1038/s41598-018-29235-7PubMedGoogle Scholar
- 43.Distinct and dynamic activation profiles of circulating dendritic cells and monocytes in mild COVID-19 and after yellow fever vaccinationEur. J. Immunol. 53:e2250090https://doi.org/10.1002/eji.202250090PubMedGoogle Scholar
- 44.Interferon-induced activation of dendritic cells and monocytes by yellow fever vaccination correlates with early antibody responsesProc. Natl. Acad. Sci. U. S. A. 122:e2422236122https://doi.org/10.1073/pnas.2422236122PubMedGoogle Scholar
- 45.Programming the magnitude and persistence of antibody responses with innate immunityNature 470:543–547https://doi.org/10.1038/nature09737PubMedGoogle Scholar
- 46.Mimicking immune signatures of flavivirus infection with targeted adjuvants improves dengue subunit vaccine immunogenicityNPJ Vaccines 4:27https://doi.org/10.1038/s41541-019-0119-3PubMedGoogle Scholar
- 47.Molecular and Cellular Dynamics in the Skin, the Lymph Nodes, and the Blood of the Immune Response to Intradermal Injection of Modified Vaccinia Ankara VaccineFront. Immunol. 9:870https://doi.org/10.3389/fimmu.2018.00870PubMedGoogle Scholar
- 48.Metabolic stability and epigenesis in randomly constructed genetic netsJ. Theor. Biol. 22:437–467https://doi.org/10.1016/0022-5193(69)90015-0PubMedGoogle Scholar
- 49.Hard-wired heterogeneity in blood stem cells revealed using a dynamic regulatory network modelBioinformatics 29:i80–i88https://doi.org/10.1093/bioinformatics/btt243PubMedGoogle Scholar
- 50.Diversity and Plasticity of Th Cell Types Predicted from Regulatory Network ModellingPLOS Comput. Biol. 6:e1000912https://doi.org/10.1371/journal.pcbi.1000912PubMedGoogle Scholar
- 51.A Mechanistic Computational Model Reveals That Plasticity of CD4+ T Cell Differentiation Is a Function of Cytokine Composition and DosageFront. Physiol. 9:878https://doi.org/10.3389/fphys.2018.00878PubMedGoogle Scholar
- 52.Mathematical Modelling of Cell-Fate Decision in Response to Death Receptor EngagementPLOS Comput. Biol. 6:e1000702https://doi.org/10.1371/journal.pcbi.1000702PubMedGoogle Scholar
- 53.Mathematical Modelling of Molecular Pathways Enabling Tumour Cell Invasion and MigrationPLOS Comput. Biol. 11:e1004571https://doi.org/10.1371/journal.pcbi.1004571PubMedGoogle Scholar
- 54.Boolean modeling identifies Greatwall/MASTL as an important regulator in the AURKA network of neuroblastomaCancer Lett. 371:79–89https://doi.org/10.1016/j.canlet.2015.11.025PubMedGoogle Scholar
- 55.Integrative modelling of the influence of MAPK network on cancer cell fate decisionPLoS Comput. Biol. 9:e1003286https://doi.org/10.1371/journal.pcbi.1003286PubMedGoogle Scholar
- 56.Inference of an Integrative, Executable Network for Rheumatoid Arthritis Combining Data-Driven Machine Learning Approaches and a State-of-the-Art Mechanistic Disease MapJ. Pers. Med. 11:785https://doi.org/10.3390/jpm11080785PubMedGoogle Scholar
- 57.Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against EbolaNPJ Vaccines 8:174https://doi.org/10.1038/s41541-023-00767-yPubMedGoogle Scholar
- 58.A model for establishment, maintenance and reactivation of the immune response after vaccination against Ebola virusJ. Theor. Biol. 495:110254https://doi.org/10.1016/j.jtbi.2020.110254PubMedGoogle Scholar
- 59.Modeling antibody dynamics following herpes zoster indicates that higher varicella-zoster virus viremia generates more VZV-specific antibodiesFront. Immunol. 14:1104605https://doi.org/10.3389/fimmu.2023.1104605PubMedGoogle Scholar
- 60.A qualitatively validated mathematical-computational model of the immune response to the yellow fever vaccineBMC Immunol. 19:15https://doi.org/10.1186/s12865-018-0252-1PubMedGoogle Scholar
- 61.Validation of a yellow fever vaccine model using data from primary vaccination in children and adults, re-vaccination and dose-response in adults and studies with immunocompromised individualsBMC Bioinformatics 21:551https://doi.org/10.1186/s12859-020-03845-3PubMedGoogle Scholar
- 62.An ODE-based mixed modelling approach for B- and T-cell dynamics induced by Varicella-Zoster Virus vaccines in adults shows higher T-cell proliferation with Shingrixthan with VarilrixVaccine 37:2537–2553https://doi.org/10.1016/j.vaccine.2019.03.075PubMedGoogle Scholar
- 63.Dependence of CD8 T Cell Response upon Antigen Load During Primary InfectionBull. Math. Biol. 81:2553–2568https://doi.org/10.1007/s11538-019-00618-9PubMedGoogle Scholar
- 64.Dynamics of the Humoral Immune Response to a Prime-Boost Ebola Vaccine: Quantification and Sources of VariationJ. Virol. 93:e00579-19https://doi.org/10.1128/jvi.00579-19PubMedGoogle Scholar
- 65.Patient-specific Boolean models of signalling networks guide personalised treatmentseLife 11:e72626https://doi.org/10.7554/eLife.72626PubMedGoogle Scholar
- 66.Mechanistic models versus machine learning, a fight worth fighting for the biological community?Biol. Lett. 14:20170660https://doi.org/10.1098/rsbl.2017.0660PubMedGoogle Scholar
- 67.Concepts in Boolean network modeling: What do they all mean?Comput. Struct. Biotechnol. J. 18:571–582https://doi.org/10.1016/j.csbj.2020.03.001PubMedGoogle Scholar
- 68.KEGG: Kyoto Encyclopedia of Genes and GenomesNucleic Acids Res. 28:27–30https://doi.org/10.1093/nar/28.1.27PubMedGoogle Scholar
- 69.A systematic approach to orient the human protein-protein interaction networkNat. Commun. 10:3015https://doi.org/10.1038/s41467-019-10887-6PubMedGoogle Scholar
- 70.CellMarker 2.0: an updated database of manually curated cell markers in human/mouse and web tools based on scRNA-seq dataNucleic Acids Res. 51:D870–D876https://doi.org/10.1093/nar/gkac947PubMedGoogle Scholar
- 71.Proteomics. Tissue-based map of the human proteomeScience 347:1260419https://doi.org/10.1126/science.1260419PubMedGoogle Scholar
- 72.Cynomolgus macaques as a translational model of human immune responses to yellow fever 17D vaccinationJ. Virol. 98:e0151623https://doi.org/10.1128/jvi.01516-23PubMedGoogle Scholar
- 73.STEM: a tool for the analysis of short time series gene expression dataBMC Bioinformatics 7:191https://doi.org/10.1186/1471-2105-7-191PubMedGoogle Scholar
- 74.Some methods for classification and analysis of multivariate observationsIn: Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability, Volume 1: Statistics University of California Press pp. 281–298Google Scholar
- 75.Combining Zhegalkin Polynomials and SAT Solving for Context-specific Boolean Modeling of Biological SystemsIEEE/ACM Trans. Comput. Biol. Bioinform. 21:2188–2199https://doi.org/10.1109/tcbb.2024.3456302PubMedGoogle Scholar
- 76.Functional cartography of complex metabolic networksNature 433:895–900https://doi.org/10.1038/nature03288PubMedGoogle Scholar
- 77.Capturing dynamic relevance in Boolean networks using graph theoretical measuresBioinformatics 37:3530–3537https://doi.org/10.1093/bioinformatics/btab277PubMedGoogle Scholar
- 78.Impact of individual nodes in Boolean network dynamicsEurophys. Lett. 99:58006https://doi.org/10.1209/0295-5075/99/58006Google Scholar
- 79.The effective graph reveals redundancy, canalization, and control pathways in biochemical regulation and signalingProc. Natl. Acad. Sci. 118:e2022598118https://doi.org/10.1073/pnas.2022598118PubMedGoogle Scholar
- 80.Canalization of Development and the Inheritance of Acquired CharactersNature 150:563–565https://doi.org/10.1038/150563a0Google Scholar
- 81.A model of transcriptional regulatory networks based on biases in the observed regulation rulesComplexity 7:23–40https://doi.org/10.1002/cplx.10022Google Scholar
- 82.Gene Ontology: tool for the unification of biologyNat. Genet. 25:25–29https://doi.org/10.1038/75556PubMedGoogle Scholar
- 83.The Gene Ontology Resource: 20 years and still GOing strongNucleic Acids Res. 47:D330–D338https://doi.org/10.1093/nar/gky1055PubMedGoogle Scholar
- 84.GSEApy: a comprehensive package for performing gene set enrichment analysis in PythonBioinformatics 39:btac757https://doi.org/10.1093/bioinformatics/btac757PubMedGoogle Scholar
- 85.Poxvirus host cell entryCurr. Opin. Virol. 2:20–27https://doi.org/10.1016/j.coviro.2011.11.007PubMedGoogle Scholar
- 86.Membrane fusion during poxvirus entrySemin. Cell Dev. Biol. 60:89–96https://doi.org/10.1016/j.semcdb.2016.07.015PubMedGoogle Scholar
- 87.Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In VivoSci. Rep. 7:8580https://doi.org/10.1038/s41598-017-08719-yPubMedGoogle Scholar
- 88.Preclinical studies of a modified vaccinia virus Ankara-based HIV candidate vaccine: antigen presentation and antiviral effectJ. Virol. 84:5314–5328https://doi.org/10.1128/jvi.02329-09PubMedGoogle Scholar
- 89.Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade CPloS One 7:e35485https://doi.org/10.1371/journal.pone.0035485PubMedGoogle Scholar
- 90.Modified Vaccinia Virus Ankara Triggers Type IIFN Production in Murine Conventional Dendritic Cells via a cGAS/STING-Mediated Cytosolic DNA-Sensing PathwayPLoS Pathog. 10:e1003989https://doi.org/10.1371/journal.ppat.1003989PubMedGoogle Scholar
- 91.Single-cell analysis reveals divergent responses of human dendritic cells to the MVA vaccineSci. Signal. 14:eabd9720https://doi.org/10.1126/scisignal.abd9720PubMedGoogle Scholar
- 92.Quantitative proteomics defines mechanisms of antiviral defence and cell death during modified vaccinia Ankara infectionNat. Commun. 14:8134https://doi.org/10.1038/s41467-023-43299-8PubMedGoogle Scholar
- 93.Diversity of cell death signaling pathways in macrophages upon infection with modified vaccinia virus Ankara (MVA)Cell Death Dis. 12:1011https://doi.org/10.1038/s41419-021-04286-3PubMedGoogle Scholar
- 94.Modified vaccinia virus Ankara can activate NF-κΒ transcription factors through a double-stranded RNA-activated protein kinase (PKR)-dependent pathway during the early phase of virus replicationVirology 391:177–186https://doi.org/10.1016/j.virol.2009.06.012PubMedGoogle Scholar
- 95.The complete DNA sequence of vaccinia virusVirology 179:247–266https://doi.org/10.1016/0042-6822(90)90294-2PubMedGoogle Scholar
- 96.Full Genome Sequence of the Western Reserve Strain of Vaccinia Virus Determined by Third-Generation SequencingGenome Announc. 6:e01570https://doi.org/10.1128/genomea.01570-17PubMedGoogle Scholar
- 97.The Poxvirus Protein A52R Targets Toll-like Receptor Signaling Complexes to Suppress Host DefenseJ. Exp. Med. 197:343–351https://doi.org/10.1084/jem.20021652PubMedGoogle Scholar
- 98.Poxvirus protein N1L targets the I-kappaB kinase complex, inhibits signaling to NF-kappaB by the tumor necrosis factor superfamily of receptors, and inhibits NF-kappaB and IRF3 signaling by toll-like receptorsJ. Biol. Chem. 279:36570–36578https://doi.org/10.1074/jbc.m400567200PubMedGoogle Scholar
- 99.Innate immune response to viral infectionCytokine 43:336–341https://doi.org/10.1016/j.cyto.2008.07.009PubMedGoogle Scholar
- 100.Synchronism versus asynchronism in monotonic Boolean automata networksNat. Comput. 17:393–402https://doi.org/10.1007/s11047-016-9608-8Google Scholar
- 101.A guiding map for inflammationNat. Immunol. 18:826–831https://doi.org/10.1038/ni.3790PubMedGoogle Scholar
- 102.Double-stranded RNA in vaccinia virus infected cellsNature 222:940–944https://doi.org/10.1038/222940a0PubMedGoogle Scholar
- 103.Recombinant Modified Vaccinia Virus Ankara Generating Excess Early Double-Stranded RNA Transiently Activates Protein Kinase R and Triggers Enhanced Innate Immune ResponsesJ. Virol. 88:14396–14411https://doi.org/10.1128/jvi.02082-14PubMedGoogle Scholar
- 104.Poxviruses package viral redox proteins in lateral bodies and modulate the host oxidative responsePLoS Pathog. 18:e1010614https://doi.org/10.1371/journal.ppat.1010614PubMedGoogle Scholar
- 105.Vaccinia virus modulates the redox environment by inhibiting reactive oxygen and nitrogen species with increased activity of endogenous antioxidant enzymesSci. Rep. 15:29771https://doi.org/10.1038/s41598-025-14433-xPubMedGoogle Scholar
- 106.Immune Profiles Identification by Vaccinomics After MVA Immunization in Randomized Clinical StudyFront. Immunol. 11:586124https://doi.org/10.3389/fimmu.2020.586124PubMedGoogle Scholar
- 107.Vaccinia Virus Protein C6 Is a Virulence Factor that Binds TBK-1 Adaptor Proteins and Inhibits Activation of IRF3 and IRF7PLoSPathog. 7:e1002247https://doi.org/10.1371/journal.ppat.1002247PubMedGoogle Scholar
- 108.Viral targeting of DEAD box protein 3 reveals its role in TBK1/IKKε-mediated IRF activation EMBO 27:2147–2157https://doi.org/10.1038/emboj.2008.143Google Scholar
- 109.Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulenceJ. Exp. Med. 201:1007–1018https://doi.org/10.1084/jem.20041442PubMedGoogle Scholar
- 110.Vaccinia Virus Immunomodulator A46: Destructive Interactions with MAL and MyD88 Shown by Negative-Stain Electron MicroscopyStructure 28:1271–1287.e5https://doi.org/10.1016/j.str.2020.09.007PubMedGoogle Scholar
- 111.Vaccinia virus protein N2 is a nuclear IRF3 inhibitor that promotes virulenceJ. Gen. Virol. 94:2070–2081https://doi.org/10.1099/vir.0.054114-0PubMedGoogle Scholar
- 112.The conserved poxvirus membrane entry-fusion apparatus component OPG147 targets MITA/STING for immune evasionPLoS Pathog. 21:e1013198https://doi.org/10.1371/journal.ppat.1013198PubMedGoogle Scholar
- 113.Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathwayNat. Immunol. 9:11571164https://doi.org/10.1038/ni.1645PubMedGoogle Scholar
- 114.mTOR Dysregulation by Vaccinia Virus F17 Controls Multiple Processes with Varying Roles in InfectionJ. Virol. 93:e00784-19https://doi.org/10.1128/jvi.00784-19PubMedGoogle Scholar
- 115.The Interferon System and Vaccinia Virus Evasion MechanismsJ. Interferon Cytokine Res. 29:581–598https://doi.org/10.1089/jir.2009.0073PubMedGoogle Scholar
- 116.Beyond Boolean: Ternary networks and dynamicsChaos Interdiscip. J. Nonlinear Sci. 32:083117https://doi.org/10.1063/5.0097874PubMedGoogle Scholar
- 117.Bma: Visual Tool for Modeling and Analyzing Biological NetworksIn:
- Madhusudan P
- Seshia SA
- 118.GINsim: A software suite for the qualitative modelling, simulation and analysis of regulatory networksBiosystems 84:91–100https://doi.org/10.1016/j.biosystems.2005.10.003PubMedGoogle Scholar
- 119.MaBoSS 2.0: an environment for stochastic Boolean modelingBioinformatics 33:2226–2228https://doi.org/10.1093/bioinformatics/btx123PubMedGoogle Scholar
- 120.Reconciling qualitative, abstract, and scalable modeling of biological networksNat. Commun. 11:4256https://doi.org/10.1038/s41467-020-18112-5PubMedGoogle Scholar
- 121.Building a modular and multi-cellular virtual twin of the synovial joint in Rheumatoid ArthritisNPJDigit. Med. 7:379https://doi.org/10.1038/s41746-024-01396-yPubMedGoogle Scholar
- 122.PhysiBoSS: a multi-scale agent-based modelling framework integrating physical dimension and cell signallingBioinformatics 35:1188–1196https://doi.org/10.1093/bioinformatics/bty766PubMedGoogle Scholar
- 123.Perturbomics: CRISPR-Cas screening-based functional genomics approach for drug target discoveryExp. Mol. Med. 57:1443–1454https://doi.org/10.1038/s12276-025-01487-0PubMedGoogle Scholar
- 124.scPerturb: harmonized single-cell perturbation dataNat. Methods 21:531–540https://doi.org/10.1038/s41592-023-02144-yPubMedGoogle Scholar
- 125.The IUPHAR/BPS Guide to PHARMACOLOGY in 2024Nucleic Acids Res. 52:D1438–D1449https://doi.org/10.1093/nar/gkad944PubMedGoogle Scholar
- 126.Personalization of Logical Models With Multi-Omics DataAllows Clinical Stratification of PatientsFront. Physiol. 9:1965https://doi.org/10.3389/fphys.2018.01965PubMedGoogle Scholar
- 127.Integrating Patient-Specific Information into Logic Models of Complex Diseases: Application to Acute Myeloid LeukemiaJ. Pers. Med. 11:117https://doi.org/10.3390/jpm11020117PubMedGoogle Scholar
- 128.Building digital twins of the human immune system: toward a roadmapNPJ Digit. Med. 5:64https://doi.org/10.1038/s41746-022-00610-zPubMedGoogle Scholar
- 129.Digital twins in medicineNat. Comput. Sci. 4:184–191https://doi.org/10.1038/s43588-024-00607-6PubMedGoogle Scholar
- 130.Immune digital twins for complex human pathologies: applications, limitations, and challengesNpj Syst. Biol. Appl. 10:1–14https://doi.org/10.1038/s41540-024-00450-5PubMedGoogle Scholar
Article and author information
Author information
Version history
- Preprint posted:
- Sent for peer review:
- Reviewed Preprint version 1:
Cite all versions
You can cite all versions using the DOI https://doi.org/10.7554/eLife.111935. This DOI represents all versions, and will always resolve to the latest one.
Copyright
© 2026, Deman et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
- views
- 0
- downloads
- 0
- citations
- 0
Views, downloads and citations are aggregated across all versions of this paper published by eLife.